What to expect from Charles River Laboratories's (CRL) Q3 earnings

What happened

Charles River Laboratories will report third-quarter earnings Wednesday before the market opens. Last quarter it reported revenue of $1.00 billion, down 2.7% from a year earlier, beating analyst revenue and earnings-per-share estimates. Analysts now expect revenue to fall 4.4% year on year this quarter.

Confirmed

Global impact / market context

A 4.4% expected revenue decline, steeper than last year's flat result, points to weaker demand for the company's lab services. If sales fall as forecast, profit per sale and cash available could come under pressure, which matters to investors judging whether the business is stabilizing.

Analyst inference

Peers in drug development inputs and services have already reported mixed third-quarter results, with West Pharmaceutical Services beating revenue expectations by 5.7%. Analyst estimates for Charles River were largely reconfirmed over the past 30 days, suggesting no major forecast changes ahead of the report.

Analyst inference

What to watch

1. Watch whether reported revenue meets the expected 4.4% year-on-year decline, and whether earnings per share, which means profit divided by shares outstanding, again beats analyst estimates as it did last quarter. Confirmed
2. Watch for any company guidance on future sales and costs, since management may update its outlook for demand in lab services and for capital spending, which means money put into long-term assets. Proposed
3. Watch how peer results, including West Pharmaceutical's 8.7% revenue growth, shape investor expectations for Charles River, since weak or strong peer demand can hint at industry-wide trends. Analyst inference

Evidence

• stockstory.org